ERBB2 and breast carcinoma: PEONY is a randomized, double-blind, placebo-controlled, phase III study that reports the long-term efficacy and safety of the addition of pertuzumab to trastuzumab in both the neoadjuvant and adjuvant setting in HER2-positive early breast cancer.